CooperCompanies and EssilorLuxottica have finalised a joint venture agreement for SightGlass Vision. The collaboration will accelerate the commercialisation of novel spectacle lens technologies to expand the myopia management category. SightGlass Vision’s Diffusion Optics Technology incorporates thousands of micro-dots into the lens that softly scatter light to reduce contrast on the retina, which is intended to reduce myopia progression in children. EssilorLuxottica’s co-Chief Operating Officer Norbert Gorny, said his company was thrilled to see the first SightGlass Vision products start to reach the market.
“Together with eye care professionals, we will be able to grow awareness about existing solutions and improve access to technologies that can help children today and in their future lives,” he said.
Dan McBride, Chief Operating Officer and General Counsel at CooperCompanies said, “Adding spectacle lenses with SightGlass Vision technology to our portfolio of myopia management products translates into better eyesight and brighter lives for countless children. SightGlass Vision’s commitment to clinically based performance fits well with CooperVision, which has conducted the world’s longestrunning myopia management clinical study and is committed to establishing myopia management as a standard of care for affected children.”
Myopia is the leading cause of visual impairment in children and, over time, may contribute to an increased risk of developing permanent vision impairment, including macular degeneration, retinal detachment, cataract and glaucoma, and blindness associated with high myopia.1
Reference
- Tideman JW et al. Association of axial length with risk of uncorrectable visual impairment for Europeans with myopia. JAMA Ophthalmol. 2016;134:1355-1363
